Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2017-04-04 Capital/Financing Update
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Botanix Raises A$7.4 Million in Oversubscribed Placement 2 pages 285.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 5 April 2017 announcing that Botanix Pharmaceuticals has received commitments to raise A$7.4 million through an oversubscribed placement. It details the placement structure, use of funds, and upcoming shareholder meeting for approval of the second tranche. The content focuses on capital raising and financing activities, including share issuance and shareholder approval processes. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a regulatory filing or announcement of voting results. The primary subject is fundraising and capital structure update. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief announcement or notice, supporting a high confidence classification.
2017-04-04 English
Capital Raising Presentation 32 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is titled 'Capital Raising Presentation' and is dated 5 April 2017. It is an investor presentation detailing a capital raising via a placement, including the structure, terms, use of funds, timetable, corporate overview, investment highlights, senior leadership, and strategic focus. The content is focused on financing activities and investor information rather than financial results or regulatory filings. The document is lengthy (15,000 characters) and contains detailed presentation material rather than a brief announcement or a report. Therefore, it fits the category of an Investor Presentation (IP) rather than a Capital/Financing Update (CAP) which would be more concise or an announcement. The presence of detailed slides and strategic information confirms this classification.
2017-04-04 English
Reinstatement to official quotation 1 page 277.8KB
Delisting Announcement Classification · 90% confidence The document is a market release announcing the reinstatement of Botanix Pharmaceuticals Ltd to official quotation on the stock exchange. It mentions that the reinstatement will occur immediately following a capital raising announcement. The document is short (601 characters) and does not contain financial data or detailed report content. It is an official notice related to the company's stock listing status, which fits the category of a Delisting Announcement or reinstatement notice. Since it is about reinstatement to official quotation (i.e., relisting), it aligns most closely with the Delisting Announcement category (DLST), which covers official notices about stock removal or reinstatement on an exchange. Confidence is high due to the clear context and content.
2017-04-04 English
Suspension from Official Quotation 2 pages 584.2KB
Regulatory Filings Classification · 95% confidence The document is a market release from Botanix Pharmaceuticals Limited dated April 2017, announcing a suspension of trading of its securities on the Australian Securities Exchange (ASX). The text references a voluntary suspension request due to a pending capital raising announcement. There are no financial statements, detailed financial data, or report contents included. The document is short (2391 characters) and serves as an official notice of suspension rather than a financial report or capital raising update itself. According to the classification rules, this is an official announcement related to trading status, specifically a suspension notice, which fits best under Delisting Announcement (DLST) or Regulatory Filings (RNS). However, since the company is not delisting but only suspending trading temporarily, the appropriate category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. Confidence is high due to clear context and document content.
2017-04-03 English
Trading Halt 2 pages 680.3KB
Capital/Financing Update Classification · 95% confidence The document is a market release from Botanix Pharmaceuticals Limited dated 31 March 2017, requesting a trading halt on its securities. The reason given is the intention to make an announcement regarding a capital raising. The document is short (2134 characters) and does not contain any financial data or detailed report content. It is an announcement related to capital raising but does not provide the actual capital raising details or financial information. According to the rules, announcements about trading halts or capital raising intentions without substantive financial data or detailed financing updates are classified as Capital/Financing Update (CAP).
2017-03-30 English
Botanix Receives Approval for Synthetic Cannabidiol Trial 2 pages 393.5KB
Capital/Financing Update Classification · 90% confidence The document is an ASX/Media Release dated 30 March 2017 announcing that Botanix Pharmaceuticals has received approval from the Human Research Ethics Committee to conduct clinical trials for a synthetic cannabidiol product. It discusses the initiation of clinical studies, regulatory approvals, and future plans but does not contain financial statements, detailed financial data, or comprehensive management analysis. The document is relatively short (4300 characters) and serves as a news announcement about a clinical trial approval rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content is best classified as a Capital/Financing Update (CAP) because it relates to a significant development in the company's product pipeline and regulatory progress, which can impact the company's capital and financing outlook. Confidence is high given the clear nature of the announcement and its focus on clinical trial approval and development progress.
2017-03-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.